US Patent Number
Mithramycin derivatives and their pharmaceutically acceptable salts are disclosed. The mithramycin derivatives can be used in the treatment of Ewing sarcoma or other cancer or neuro-disease associated with an aberrant erythroblast transformation- specific transcription factor.
University of Kentucky Research Foundation, Lexington, KY (US)
Rohr, Jürgen; Scott, Daniel; Leggas, Markos; Chen, Jhong-Min; and Tsodikov, Oleg V., "Semi-Synthetic Mithramycin Derivatives with Anti-Cancer Activity" (2016). Pharmaceutical Sciences Faculty Patents. 160.